NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
Clinical Trials
38 trialsNCT05235100 2025-12-11
SPARE-02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05156970 2025-07-31
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT04625803 2025-06-17
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Phase 2 Completed
NCT04195828 2025-04-01
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Completed
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT06376773 2024-04-19
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Fujian Medical University
Completed
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT04393506 2023-11-22
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 1 Completed
NCT03267121 2023-10-17
A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT03180476 2023-04-14
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT02976896 2023-02-16
Poetry-1
Sun Yat-sen University
Phase 2 Completed
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT04350190 2023-01-13
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Completed
NCT02945852 2022-07-19
Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Zhejiang Cancer Hospital
Phase 2 Completed
NCT03254654 2022-04-20
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Fudan University
Phase 2 Completed
NCT03104283 2022-03-15
Apatinib for the Elderly Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Completed
NCT04188847 2022-03-15
First-line Chemotherapy for Recurrent Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Completed
NCT04690231 2022-03-15
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Peking University People's Hospital
Phase NA Completed
NCT03243838 2022-02-02
LANCET
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT02731352 2022-01-20
Study of Apatinib in Patients With Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 2 Completed
NCT04047017 2021-07-30
GTN
Peking Union Medical College Hospital
Phase 2 Completed
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT02645864 2021-03-18
Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
Peking University
Phase 1 Completed
NCT02878057 2021-01-27
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT03274011 2021-01-26
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Completed
NCT03251443 2020-12-02
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT03547804 2020-12-01
MK 01
The First Hospital of Jilin University
Phase 2 Completed
NCT04338438 2020-11-10
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Beijing Friendship Hospital
Phase 2 Completed
NCT03394287 2020-10-23
A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT03376958 2019-07-25
Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
Zhengzhou University
Phase 4 Completed
NCT02998242 2019-05-21
ARCAP
Sichuan Provincial People's Hospital
Phase NA Completed
NCT03660761 2019-04-16
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT02711007 2018-04-23
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Peking University People's Hospital
Phase 2/3 Completed
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT01176669 2015-09-09
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Fudan University
Phase 2 Completed
NCT01653561 2013-12-03
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT00970138 2011-07-12
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Phase 2/3 Completed